| 多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的疗效和安全性 |
| |
| 引用本文： | 裘光贤,周兆春,王婕.多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的疗效和安全性[J].药学服务与研究,2011,11(3):210-212. |
| |
| 作者姓名： | 裘光贤 周兆春 王婕 |
| |
| 作者单位： | 上海市黄浦区中心医院肿瘤科,上海,200002 |
| |
| 摘 要： | 目的:观察多西他赛联合奥沙利铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法:将60例晚期NSCLC病人随机分为两组,每组30例。治疗组第1天以多西他赛75 mg/m2,奥沙利铂150 mg/m2静脉滴注;对照组第1天以多西他赛75 mg/m2,顺铂80 mg/m2静脉滴注。4周为一疗程,治疗2~3个疗程。结果:治疗组病人完全缓解1例,部分缓解14例,稳定11例,进展4例,有效率50.0%;对照组病人部分缓解11例,稳定11例,进展8例,有效率36.7%。治疗组的有效率明显高于对照组(P<0.05)。治疗组病人的卡氏评分高于对照组(P<0.05),但中位疾病进展时间和1年生存率无显著性差异(P>0.05)。两种化疗方案的主要不良反应均为白细胞减少、胃肠道反应和肝功能异常,但治疗组发生率低于对照组(P<0.05),大部分病人能耐受。结论:多西他赛联合奥沙利铂治疗晚期NSCLC的疗效较好,病人能耐受这两种药品的不良反应,生活质量较高。
|
| 关 键 词： | 非小细胞肺癌 多西他赛 奥沙利铂 顺铂 药物疗法 联合 安全性 |
Efficacy and safety of docetaxel combined with oxaliplatin in treatment of patients with advanced non-small-cell lung cancer |
| |
| QIU GuangXian,ZHOU ZhaoChun,WANG Jie.Efficacy and safety of docetaxel combined with oxaliplatin in treatment of patients with advanced non-small-cell lung cancer[J].Pharmaceutical Care and Research,2011,11(3):210-212. |
| |
| Authors: | QIU GuangXian ZHOU ZhaoChun WANG Jie |
| |
| Institution: | QIU GuangXian,ZHOU ZhaoChun,WANG Jie(Department of Oncology,Central Hospital of Shanghai Huangpu District,Shanghai 200002,China) |
| |
| Abstract: | Objective:To observe the efficacy and safety of combined treatment with docetaxel and oxaliplatin in patients with advanced non-small-cell lung cancer(NSCLC).Methods: Sixty patients with advanced NSCLC were randomly divided into treatment group and control group of 30 patients each.The patients in treatment group were intravenously given 75 mg/m2 docetaxel and 150 mg/m2 oxaliplatin on the first day,while the patients in control group were given 75 mg/m2 docetaxel and 80 mg/m2 cisplatin.One treatment course ... |
| |
| Keywords: | non-small-cell lung cancer docetaxel oxaliplatin cisplatin drug therapy combination safety |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
